top of page

THERAPEUTIC AREAS > IMMUNOLOGY
Immunology
Our immunology research is dedicated to addressing diseases caused by immune system dysfunction - including autoimmune and inflammatory disorders that affect hundreds of millions worldwide. It is estimated that approximately 600‑800 million people globally live with autoimmune condition
Our research interests
We focus on uncovering new therapeutic targets and pathways across both common and rare immune‑mediated diseases. Some of the most frequently diagnosed immune challenge diseases include rheumatoid arthritis, psoriasis, type 1 diabetes, and lupus. NCBI +1 Our work bridges discovery research, translational science, and clinical development to bring promising therapies to patients more efficiently.
Bringing precision medicine to immunology
We’ve made significant investments over the past few year and hope to usher in a new era in immunology. We're pursuing biomarkers that could play a key role in identifying people who are more likely to respond to therapies. The ultimate goal is to be able to deliver the right medicine for the right patient at the right time.

Exploring new modalities
To meet the demands of complex immune disorders, we leverage advanced therapeutic modalities such as biologics, cell therapies, and precision‑targeted interventions. These novel approaches aim to bring durable responses and better long‑term outcomes where traditional treatments may fall short.

From Laboratory Discovery to Patient Impact
Learn more about the experience of living with HS and hear from Genventis scientists as they work to better understand and address patients’ unmet needs.
Immunology focus areas
Advancing research and innovative therapies to better understand and treat immune-mediated diseases.
Innovation strengths
Across disease areas and development stages, we follow 3 tenets to drive innovation forward.

Related links

Vaccines
We’ve been discovering, developing, supplying and delivering vaccines to help prevent disease for over 130 years.

Our teams of researchers and scientists are pushing the boundaries of cancer research to discover more effective anticancer therapies.

Our science-led strategy is key to delivering long-term value for patients, employees, and shareholders.
bottom of page